載入中
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
前收盤價
US$1.03
−US$0.01 · -0.96%
盤前
US$0.9865
−US$0.0435 · -4.22%
10月12日 上午8:04 ET
盤中時間採用ET。市場資料可能有所延遲。
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
日內區間
目前US$1.03
52週區間
目前US$1.03
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
44
合理估值
情緒
48
多空交錯
風險
74
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
日內區間
目前US$1.03
52週區間
目前US$1.03
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 4.5萬 USD | 44.9萬 USD |
| 銷貨成本 | 165.1萬 USD | — | 125.6萬 USD | 27.4萬 USD | 9.4萬 USD |
| 毛利 | −165.1萬 USD | — | −125.6萬 USD | −22.9萬 USD | 35.5萬 USD |
| 研究與開發 | 973.7萬 USD | 887.8萬 USD | 1300.8萬 USD | 725.7萬 USD | 467.4萬 USD |
| 銷售、一般及管理費用 | 1050.3萬 USD | 1289.8萬 USD | 1598.4萬 USD | 1564.2萬 USD | 616.3萬 USD |
| 營業費用 | 1858.9萬 USD | 2177.6萬 USD | 2773.6萬 USD | 2289.9萬 USD | 1083.7萬 USD |
| 利息支出 | 20.7萬 USD | 93.3萬 USD | 374.9萬 USD | 15.8萬 USD | 61.4萬 USD |
| 折舊和攤銷 | 165.1萬 USD | 153.5萬 USD | 125.6萬 USD | 25.3萬 USD | 15.3萬 USD |
| 營業利益 | −2024萬 USD | −2177.6萬 USD | −2899.2萬 USD | −2312.8萬 USD | −1048.2萬 USD |
| 淨利 | −1990.6萬 USD | −2214.3萬 USD | −2921.6萬 USD | −2542.7萬 USD | −1093.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.50
上漲空間 433.98%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年7月31日 | 1:16 | — | — |
股票分割 | 2025年8月5日 | 1:12 | — | — |
股票分割 | 2024年7月15日 | 1:10 | — | — |
已生效 2026年7月31日
1:16
已生效 2025年8月5日
1:12
已生效 2024年7月15日
1:10
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
